
Kyntra Bio fell 76.6% from $8.70 to $2.04, behind the S&P 500's +10.0%. Its worst day was Nov 17 (−36.3%), and its low came Nov 17 at $2.04.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kyntra Bio closed at its highest level of the year, 15.4% above where the year started.
+19.8%, the year's best day · S&P 500 −0.2%
EPS of $-3.61 beat the $-3.89 estimate on $1.3M revenue (est. $1.6M).
Story events cover the past 12 months · Times ET
+5.3% · S&P 500 +0.3%
EPS of $-3.74 was reported on $3.7M revenue.
+6.3% · S&P 500 −0.2%
EPS of $-4.68 missed the $-3.18 estimate on $-1.5M revenue (est. $2.0M).
+0.1% · S&P 500 −0.2%
EPS of $-3.42 missed the $-3.40 estimate on $1.8M revenue (est. $1.8M).
−36.3%, the year's worst day · S&P 500 −1.0%
Where it ended: a close of $2.04 on Nov 17, 2026. Up next: Q4 2026 earnings on Mar 15, 2027 (EPS est. $-3.55, revenue est. $2.3M).
Nothing in the past 12 months.
All KYNB dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KYNB and SPY from Benzinga historical bars. Not investment advice.